Retatrutide is an investigational once-weekly injectable being developed by Eli Lilly for obesity, and in clinical trials it has produced the largest weight loss of any obesity medication studied so far, up to roughly 28% to 30% of body weight at the highest doses. What sets it apart is its mechanism: it activates three hormone receptors at once (GIP, GLP-1, and glucagon), which is why it’s called a triple agonist. As of mid-2026, retatrutide is not yet approved by the FDA. It’s in late-stage (phase 3) trials, so it isn’t available by prescription yet, but the data has made it one of the most closely watched drugs in obesity medicine.<\/p>\n
To understand retatrutide, it helps to see how it builds on the drugs already on the market. Semaglutide (the ingredient in Ozempic and Wegovy) activates one receptor, GLP-1. Tirzepatide (Mounjaro and Zepbound) activates two, GLP-1 and GIP. Retatrutide adds a third, glucagon.<\/p>\n
That third receptor is the interesting part. GLP-1 and GIP mainly reduce appetite and improve how your body handles blood sugar. Glucagon receptor activation is thought to increase energy expenditure (how many calories your body burns) and push the liver to burn its stored fat. Combining all three appears to drive weight loss beyond what one or two pathways achieve on their own.<\/p>\n
The study that put retatrutide on the map was a phase 2 trial published in the New England Journal of Medicine in 2023<\/a>. In that 48-week study of 338 adults with obesity, participants on the highest dose (12 mg) lost an average of about 24% of their body weight, and notably, weight loss had not yet leveled off when the study ended.<\/p>\n Since then, Lilly has moved retatrutide into a large phase 3 program called TRIUMPH. Topline results from the pivotal obesity trial, TRIUMPH-1, were announced in May 2026 and showed average weight loss of roughly 28% at the highest dose over 80 weeks, with people who had more severe obesity losing up to around 30% over two years. Those are the biggest figures reported in a phase 3 obesity trial to date.<\/p>\n Here’s how retatrutide’s trial results stack up against approved options:<\/p>\n Retatrutide’s side effect profile looks broadly similar to other drugs in the class, with gastrointestinal effects (nausea, vomiting, diarrhea) being the most common, generally mild to moderate, and usually occurring during dose escalation. Trials have also reported a signal of dysesthesia, an abnormal skin sensation, at higher doses, which was generally mild. As with any investigational drug, the full safety picture becomes clearer as larger and longer trials report.<\/p>\n Retatrutide is in phase 3 trials across several conditions, including obesity, type 2 diabetes, and cardiovascular disease. Based on Lilly’s published trial timeline, an FDA submission is generally expected in late 2026 or early 2027, which means approval and availability, if the trials succeed, would likely follow after that. Nothing is guaranteed until regulators review the complete data.<\/p>\n No. It’s investigational and not FDA approved as of 2026. It can’t be prescribed outside of clinical trials, and any product marketed as retatrutide outside that setting is not an approved medication.<\/p>\n In trials it has produced larger average weight loss, but there are no head-to-head phase 3 results yet, and it also tends to come with more gastrointestinal side effects. “Better” depends on the individual, and only a provider can weigh the trade-offs for you.<\/p>\n An FDA filing is generally expected in late 2026 or early 2027, so approval would come sometime after that if the data holds up. Timelines can shift.<\/p>\n Retatrutide represents the next step in obesity pharmacology, adding a third hormone pathway to push weight loss into a range previously seen mostly with surgery. It’s promising, but it’s not here yet. If you’re ready to start now rather than wait for a drug still in trials, effective GLP-1 options are already available. You can see which treatments you’re a candidate for through TrimRx’s quiz<\/a> and talk it through with a licensed provider.<\/p>\n This information is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Retatrutide is an investigational once-weekly injectable being developed by Eli Lilly for obesity, and in clinical trials it has produced the largest weight loss…<\/p>\n","protected":false},"author":7,"featured_media":65706,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[],"class_list":["post-130688","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=130688"}],"version-history":[{"count":2,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130688\/revisions"}],"predecessor-version":[{"id":130690,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130688\/revisions\/130690"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/65706"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=130688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=130688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=130688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n\n
\n \nMedication<\/th>\n Receptors targeted<\/th>\n Approx. weight loss in trials<\/th>\n Status<\/th>\n<\/tr>\n<\/thead>\n \n Semaglutide (Wegovy)<\/td>\n GLP-1<\/td>\n About 15%<\/td>\n Approved<\/td>\n<\/tr>\n \n Tirzepatide (Zepbound)<\/td>\n GIP, GLP-1<\/td>\n About 20 to 22%<\/td>\n Approved<\/td>\n<\/tr>\n \n Retatrutide<\/td>\n GIP, GLP-1, glucagon<\/td>\n About 24 to 28%<\/td>\n Investigational<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n Side effects seen so far<\/h3>\n
Where it is in development<\/h3>\n
Common questions<\/h3>\n
Is retatrutide available now?<\/h4>\n
Is retatrutide better than Ozempic or Zepbound?<\/h4>\n
When will retatrutide be approved?<\/h4>\n
The bottom line<\/h3>\n